$REGN

Generating a unique summary for REGN…

AI-generated for information only — not investment advice.

Biotech, Eylea and Dupixent.

Institutions hold —% · insiders —%

No institutional filings available for this ticker.

No insider transactions reported.

Consensus score — (1 = strong buy, 5 = sell) · mean target —

No recent analyst actions.

Next report: not scheduled

No earnings history available.

No filings indexed for this ticker.

• Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

  They could both outperform the market over the medium term, but one appears to have a clear edge.

  Fri, 04 Sep 2026 18:50:00 +0000

• 2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

  Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr

  Wed, 02 Sep 2026 11:17:00 +0000

• Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?

  Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.

  Wed, 02 Sep 2026 10:30:38 +0000

• Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View

  Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...

  Sun, 30 Aug 2026 02:15:30 +0000

• Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

  Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...

  Sat, 29 Aug 2026 20:14:30 +0000

• Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

  The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of […]

  Thu, 27 Aug 2026 21:04:10 +0000

• Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials

  Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s […]

  Thu, 27 Aug 2026 12:43:00 +0000

• Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

  Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.

  Wed, 26 Aug 2026 12:01:28 +0000